Carbachol

CHEMBL14 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
182.6 g/mol
LogP
Phase
4

A cholinomimetic agent that stimulates both muscarinic and nicotinic receptors, used as eye drops to treat glaucoma by lowering intraocular pressure and as an intraocular agent during eye surgery to produce rapid pupil constriction. It is resistant to breakdown by cholinesterases, giving it a longer duration of action than acetylcholine. Systemic absorption can cause significant parasympathetic side effects.

分子量

182.6500 g/mol

TPSA

52.30 Ų

作用机制

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[N+](C)(C)CCOC(N)=O.[Cl-]

InChI

InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H

Molecular Formula

C6H15ClN2O2

HBD / HBA

1 / 3

可旋转键数

4

重原子数

11

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A cholinomimetic agent that stimulates both muscarinic and nicotinic receptors, used as eye drops to treat glaucoma by lowering intraocular pressure and as an intraocular agent during eye surgery to produce rapid pupil constriction. It is resistant to breakdown by cholinesterases, giving it a longer duration of action than acetylcholine. Systemic absorption can cause significant parasympathetic side effects.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Carbachol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL14. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5831. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.